Exportin 1/chromosome region maintenance 1 as a therapeutic target for lung cancer.
作者信息
Gao Weimin
机构信息
Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, Texas, USA.
出版信息
Transl Cancer Res. 2017 Feb;6(Suppl 1):S83-S86. doi: 10.21037/tcr.2017.02.35.
Abstract
摘要
相似文献
1
Exportin 1/chromosome region maintenance 1 as a therapeutic target for lung cancer.输出蛋白1/染色体区域维持蛋白1作为肺癌的治疗靶点
Transl Cancer Res. 2017 Feb;6(Suppl 1):S83-S86. doi: 10.21037/tcr.2017.02.35.
2
Exportin-1 is required for the maintenance of the planarian epidermal lineage.输出蛋白 1 对于扁形动物表皮谱系的维持是必需的。
Int J Biol Macromol. 2019 Apr 1;126:1050-1055. doi: 10.1016/j.ijbiomac.2019.01.014. Epub 2019 Jan 4.
3
The past, present, and future of CRM1/XPO1 inhibitors.CRM1/XPO1抑制剂的过去、现在与未来。
Stem Cell Investig. 2019 Feb 25;6:6. doi: 10.21037/sci.2019.02.03. eCollection 2019.
4
Importins and exportins as therapeutic targets in cancer.Importins 和 exportins 作为癌症治疗靶点。
Pharmacol Ther. 2016 Aug;164:135-43. doi: 10.1016/j.pharmthera.2016.03.020. Epub 2016 Apr 23.
5
Structural Basis of Targeting the Exportin CRM1 in Cancer.靶向癌症中输出蛋白CRM1的结构基础。
Cells. 2015 Sep 21;4(3):538-68. doi: 10.3390/cells4030538.
6
Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer.通过抑制输出蛋白-1导致p33ING1b的核内滞留：头颈部鳞状细胞癌凋亡的一个触发因素。
Cell Mol Biol (Noisy-le-grand). 2018 Apr 30;64(5):66-72.
7
A study of binding features between exportin-t and Thermus thermophilus tRNA(Phe) using a photo-cross-linking method.
Biochemistry. 2008 Aug 26;47(34):8815-21. doi: 10.1021/bi800008x. Epub 2008 Jul 30.
8
Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.通过沉默 Dicer、Drosha 和 Exportin 5 诱导膀胱尿路上皮癌的细胞增殖抑制和细胞凋亡。
J Surg Oncol. 2013 Feb;107(2):201-5. doi: 10.1002/jso.23214. Epub 2012 Jul 5.
9
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.小分子拮抗剂通过合理的基于结构的发现靶向出核蛋白 1。
J Med Chem. 2020 Apr 23;63(8):3881-3895. doi: 10.1021/acs.jmedchem.9b01663. Epub 2020 Apr 10.
10
Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).细霉素B会改变CRM1（输出蛋白1）的亚细胞分布。
Biochem Biophys Res Commun. 2017 Jun 24;488(2):253-258. doi: 10.1016/j.bbrc.2017.04.042. Epub 2017 Apr 12.
引用本文的文献
1
RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells Mediating SMAD2/3 and ERK1/2 Nuclear Transport.RanBP3通过介导SMAD2/3和ERK1/2核转运来调节慢性粒细胞白血病细胞的增殖、凋亡和化疗敏感性。
Front Oncol. 2021 Aug 24;11:698410. doi: 10.3389/fonc.2021.698410. eCollection 2021.
本文引用的文献
1
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.XPO1 依赖的核输出是 KRAS 突变型肺癌中的一个可药物靶向的弱点。
Nature. 2016 Oct 6;538(7623):114-117. doi: 10.1038/nature19771. Epub 2016 Sep 28.
2
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.采用XPO1与拓扑异构酶II抑制剂联合疗法治疗多发性骨髓瘤获得性耐药
J Hematol Oncol. 2016 Aug 24;9(1):73. doi: 10.1186/s13045-016-0304-z.
3
Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.核输出选择性抑制剂塞利尼索联合氟达拉滨和阿糖胞苷治疗儿童复发或难治性急性白血病的I期研究
J Clin Oncol. 2016 Dec;34(34):4094-4101. doi: 10.1200/JCO.2016.67.5066. Epub 2016 Oct 31.
4
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.塞利尼索（一种核输出选择性抑制剂）在晚期实体瘤患者中的首例人体I期研究，该研究为同类首创。
J Clin Oncol. 2016 Dec;34(34):4142-4150. doi: 10.1200/JCO.2015.65.3949. Epub 2016 Oct 31.
5
Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection.作为新型治疗靶点的核输出：与CRM1的联系
Curr Cancer Drug Targets. 2015;15(7):575-92. doi: 10.2174/156800961507150828223554.
6
Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.表没食子儿茶素-3-没食子酸酯增强了雷帕霉素对人肺癌A549细胞的治疗效果。
Oxid Med Cell Longev. 2015;2015:217304. doi: 10.1155/2015/217304. Epub 2015 Apr 1.
7
Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy.CRM1 过表达：肺癌发生转化表型的特征性特征，也是肺癌辅助治疗的分子靶点。
J Thorac Oncol. 2015 May;10(5):815-825. doi: 10.1097/JTO.0000000000000485.
8
Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin.多柔比星预处理增敏耐博霉素 B 肺癌细胞的化疗作用。
PLoS One. 2012;7(3):e32895. doi: 10.1371/journal.pone.0032895. Epub 2012 Mar 7.
9
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.CBS9106 是一种新型的可逆口服 CRM1 抑制剂，具有 CRM1 降解活性。
Blood. 2011 Oct 6;118(14):3922-31. doi: 10.1182/blood-2011-01-333138. Epub 2011 Aug 12.
10
CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model.CRM1 依赖性 p53 核积累在双转基因小鼠肺肿瘤模型肺病变中。
Oncol Rep. 2011 Jul;26(1):223-8. doi: 10.3892/or.2011.1279. Epub 2011 Apr 21.
Zotero 插件